Switch theme
Sign up to access all valuation multiples
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
2007
761
LTM Revenue $321M
LTM EBITDA $53.2M
$307M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Castle Biosciences has a last 12-month revenue of $321M and a last 12-month EBITDA of $53.2M.
In the most recent fiscal year, Castle Biosciences achieved revenue of $332M and an EBITDA of $38.1M.
Castle Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Castle Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $220M | $332M | XXX | XXX | XXX |
| Gross Profit | $105M | $175M | XXX | XXX | XXX |
| Gross Margin | 48% | 53% | XXX | XXX | XXX |
| EBITDA | -$45.0M | $38.1M | XXX | XXX | XXX |
| EBITDA Margin | -20% | 11% | XXX | XXX | XXX |
| Net Profit | -$67.1M | -$57.5M | XXX | XXX | XXX |
| Net Margin | -31% | -17% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Castle Biosciences's stock price is $20.
Castle Biosciences has current market cap of $574M, and EV of $307M.
See Castle Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $307M | $574M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Castle Biosciences has market cap of $574M and EV of $307M.
Castle Biosciences's trades at 1.0x LTM EV/Revenue multiple, and 5.8x LTM EBITDA.
Analysts estimate Castle Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Castle Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $307M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | XXX | XXX |
| P/E | 31.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 8.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCastle Biosciences's NTM/LTM revenue growth is -9%
Castle Biosciences's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Castle Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Castle Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Castle Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 51% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -185% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 2% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 79% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Castle Biosciences acquired XXX companies to date.
Last acquisition by Castle Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Castle Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Castle Biosciences founded? | Castle Biosciences was founded in 2007. |
| Where is Castle Biosciences headquartered? | Castle Biosciences is headquartered in United States of America. |
| How many employees does Castle Biosciences have? | As of today, Castle Biosciences has 761 employees. |
| Who is the CEO of Castle Biosciences? | Castle Biosciences's CEO is Mr. Derek J. Maetzold. |
| Is Castle Biosciences publicy listed? | Yes, Castle Biosciences is a public company listed on NAS. |
| What is the stock symbol of Castle Biosciences? | Castle Biosciences trades under CSTL ticker. |
| When did Castle Biosciences go public? | Castle Biosciences went public in 2019. |
| Who are competitors of Castle Biosciences? | Similar companies to Castle Biosciences include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Castle Biosciences? | Castle Biosciences's current market cap is $574M |
| What is the current revenue of Castle Biosciences? | Castle Biosciences's last 12-month revenue is $321M. |
| What is the current EBITDA of Castle Biosciences? | Castle Biosciences's last 12-month EBITDA is $53.2M. |
| What is the current EV/Revenue multiple of Castle Biosciences? | Current revenue multiple of Castle Biosciences is 1.0x. |
| What is the current EV/EBITDA multiple of Castle Biosciences? | Current EBITDA multiple of Castle Biosciences is 5.8x. |
| What is the current revenue growth of Castle Biosciences? | Castle Biosciences revenue growth between 2023 and 2024 was 51%. |
| Is Castle Biosciences profitable? | Yes, Castle Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
